US OptionsDetailed Quotes

ALLK240517C2500

Watchlist

0.05
0.000.00%

15min DelayTrading Mar 20 11:03 ET

0.00High0.00Low

Allakos Stock Discussion

71143235

Mar 2 02:59

$Allakos(ALLK.US)$ mark my words buyout rumors or news in 2-3 months

JCBF

Feb 1 18:18

still think it will be heading back to price gap

$Allakos(ALLK.US)$ Allakos | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.8%)
SEC announcement
·
01/29 17:30

JCBF

Jan 29 11:05

interesting

$Allakos(ALLK.US)$ huge price gap, will it make it back to 2.0?

$Allakos(ALLK.US)$ Allakos Announced Topline Data From Its Phase 2 Trial For Lirentelimab In Atopic Dermatitis (ATLAS) And Phase 2B Study In Chronic Spontaneous Urticaria (MAVERICK); The Studies Did Not Meet Their Primary Endpoints

Meltyy

Jan 3 20:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...

Moomoo AI

Dec 5, 2023 18:12

Allakos' 57% reduction in cash burn exhibits resilience, yet it's a high-risk stock due to large cash burn in comparison to market value. Future growth funding may cause substantial share dilution. The firm's ability to secure more funds and its future business growth are key considerations.